ESH Video

#ESHLYMPHOMA2024 PROGRAMME HIGHLIGHT: DEBATE 1 ON MANTLE CELL LYMPHOMA

May 22, 2024

 

4th How to Diagnose and Treat


LYMPHOMA

 

November 1-3, 2024

Stockholm, Sweden

#ESHLYMPHOMA2024

Chairpersons: Christian Buske (Ulm), Michael Crump (Toronto),
Gilles Salles (New York), Catherine Thieblemont (Paris)

 

 


 

PROGRAMME HIGHLIGHT: DEBATE 1

 

Mantle Cell lymphoma:
Optimal cellular therapy for relapsed disease CAR-T vs AlloSCT

 


Chair: Martin Dreyling (Munich)

Allogeneic stem cell transplantation is the only curative option
for relapsed Mantle Cell lymphoma
by Stephan Mielke (Stockholm)

CAR-T cell therapy is the preferred cellular therapy for patients
with relapsed Mantle Cell lymphoma
by Marie José Kersten (Amsterdam)

(with audience voting)

Friday, November 1, 2024 / 17:55-18:35

 


 

About the Conference:

ESH How to Diagnose and Treat meetings are disease-specific meetings that address state-of-the-art diagnostic and clinical management.

They are based on the presentation and analysis of real clinical cases. Voting technology is used as a self-evaluation tool and to increase scientific interaction.

 

 


 

CALL FOR ABSTRACTS & CLINICAL CASES
Deadline:  August 19th, 2024

 
Clinical Cases and abstracts are eligible to be selected for an oral or a poster presentation.

 


 

CONFERENCE MAIN SCIENTIFIC TOPICS

• Aggressive B cell lymphomas: Diffuse large B cell lymphoma,
High grade B cell lymphoma and Burkitt
• Mantle cell lymphoma
• Challenging T cell lymphomas
• Mantle Cell lymphoma: Optimal cellular therapy for
relapsed disease CAR T vs AlloSCT
• Diffuse large B cell lymphoma
• Diffuse large B-cell lymphoma: Immune based therapy
• Novelties in marginal zone lymphoma and Waldenström macroglobulinemia
• What is the optimal regimen for advanced Hodgkin’s lymphoma?
• Chronic lymphocytic leukemia
• Follicular Lymphoma
• Bispecific VS Car-T
• Immune environment in Hodgkin’s lymphoma

 

To read the preliminary programme, click here!

For more information, click here!

 


 

With the support of*:


Major Conference Partner
*******


Level 1 Conference Partner
*******

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.